Answers are grounded in this paper and cite their sources.
The oral bioavailability of cyclosporine, a substrate of both CYP3A4 and P-glycoprotein, is subject to large inter-individual variability, which requires frequent monitoring of plasma concentrations. In 1997, the study by Lown et al. showed that-in addition to hepatic CYP3A4-the expression of P-gp in the intestine significantly influences the pharmacokinetics of cyclosporine in kidney transplant patients. The results contributed considerably to a better understanding of the function of the intestinal P-glycoprotein for drug clearance.
No takes yet. Share an insight, caveat, or question.
Cascorbi et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: